Bolt Biotherapeutics (NASDAQ:BOLT) Stock Price Crosses Below 200-Day Moving Average – What’s Next?

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT)’s share price passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $5.39 and traded as low as $4.01. Bolt Biotherapeutics shares last traded at $4.12, with a volume of 43,870 shares.

Wall Street Analyst Weigh In

BOLT has been the topic of a number of recent analyst reports. Zacks Research downgraded Bolt Biotherapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, November 20th. Weiss Ratings reissued a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research note on Wednesday, January 21st. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $34.00.

Bolt Biotherapeutics Stock Performance

The company has a 50-day moving average price of $5.46 and a two-hundred day moving average price of $5.37. The company has a quick ratio of 3.57, a current ratio of 3.57 and a debt-to-equity ratio of 0.65. The stock has a market capitalization of $7.93 million, a P/E ratio of -0.18 and a beta of 0.94.

Hedge Funds Weigh In On Bolt Biotherapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Renaissance Technologies LLC increased its stake in shares of Bolt Biotherapeutics by 92.2% in the fourth quarter. Renaissance Technologies LLC now owns 55,025 shares of the company’s stock worth $301,000 after buying an additional 26,400 shares during the period. T3 Companies LLC purchased a new stake in shares of Bolt Biotherapeutics during the fourth quarter worth about $208,000. Nano Cap New Millennium Growth Fund L P bought a new stake in shares of Bolt Biotherapeutics in the fourth quarter worth about $112,000. Susquehanna International Group LLP purchased a new position in Bolt Biotherapeutics during the 3rd quarter valued at about $89,000. Finally, Shay Capital LLC purchased a new position in Bolt Biotherapeutics during the 3rd quarter valued at about $85,000. Institutional investors own 86.70% of the company’s stock.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.